Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma

por Ouerdani, A, Struemper, H, Suttle, AB, Ouellet, D, Ribba, B
Publicado 2015

Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings

por Wilson, S, Tod, M, Ouerdani, A, Emde, A, Yarden, Y, Adda Berkane, A, Kassour, S, Wei, MX, Freyer, G, You, B, Grenier, E, Ribba, B
Publicado 2015